环球律师事务所近日为基因测序仪器生产商华大智造完成10亿美元B轮融资提供了法律意见,天元律师事务所则代表领投方IDG资本,以及华大智造老股东中信证券/金石投资参与交易。

根据天元及环球的新闻稿,此次领投方还包括CPE,跟投方包括华兴新经济基金、国方资本、华泰紫金、钛信资本、上海赛领、基石资本、上海鼎峰、国泰君安创投等,老股东松禾资本等同时追加投资。此次投资创下了中国基因测序领域最大融资金额记录。

创立于2016年,华大智造是一家研发、生产和销售生命科学与医疗健康领域仪器设备、试剂耗材等相关产品的企业。其所研发制造的基因测序仪及核酸试剂盒被广泛应用在了此次新冠疫情之中。

此次B轮融资与华大智造第一轮融资仅一年之隔,其首轮募资金额为2亿美元。

环球团队此项目牵头律师为合伙人李琤、贺继红;

天元则组成两支团队,分别作为IDG资本和中信证券/金石投资的法律顾问,前者牵头律师为合伙人郑屹磊,后者牵头律师为合伙人石磊。

 

Tian Yuan, Global on COVID-19 testing equipment maker MGI Tech’s $1 bln funding

Global Law Office has advised China DNA sequencing instrument maker MGI Tech on its $1 billion series B funding, with Tian Yuan Law Firm advising lead investor IDG Capital and one of the existing investors, Citic Securities’ private equity unit Gold Stone Investment.

Citic Private Equity Funds Management also took a lead on the investment. Other investors include Huaxing New Economic Fund, Co-Stone Asset Management, the equity investment unit of brokerage Guotai Junan Securities and Shenzhen Green Pine Capital Partners.

This is by far the largest fundraising in the DNA sequencing industry in China.

Founded in 2016, MGI Tech focuses on R&D, production and sales of DNA sequencing instruments, reagents, and related products. It is well-known for the manufacturing and selling of test kits and instruments during the COVID-19 pandemic in both China and abroad. 

MGI Tech’s first round of financing was completed a year ago. It raised $200 million in that round.

The Global team was led by partners Li Cheng and He Jihong, while partners Zheng Yilei and Shi Lei led the Tian Yuan team 

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.